1. Vladimirova LYu. Usage of MEK inhibitors in oncology: results and perspectives. Advances in Current Natural Sciences = Uspekhi sovremennogo yestestvoznaniya. 2015;(3):18-30. (In Russ.)
2. Protsenko SA, Novik AV, Akhaeva ZY, Zhabina AS, Imyanitov EN, Semenova AI. Modern options in personalized therapy of metastatic cutaneous melanoma. Journal of Modern Oncology = Sovremennaya onkologiya. 2014;16(3):57-64. (In Russ.)
3. Orlova KV, Kharkevich GYu, Demidov LV. Treatment of cancer with BRAF V600 gene mutation using vemurafenib. Farmateka. 2015;(18):57-60. (In Russ.)
4. Kolbin AS, Kurylev AA, Balykina YuE, Proskurin MA. Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation. Good Clinical Practice = Kachestvennaya klinicheskaya praktika. 2017;(1):11-19. (In Russ.)